Vestipitant (INN)[1]: 98  is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor.

It is under development as a potential antiemetic and anxiolytic drug,[2][3] and as a treatment for tinnitus[4] and insomnia.

[5] This drug article relating to the gastrointestinal system is a stub.

You can help Wikipedia by expanding it.This drug article relating to the nervous system is a stub.

You can help Wikipedia by expanding it.